



Systematic review and meta-analysis of surgical drain management after the diagnosis of postoperative pancreatic fistula after pancreaticoduodenectomy: draining-tract-targeted works better than standard management

Sergio Pedrazzoli¹ · A. R. Brazzale²Received: 6 May 2020 / Accepted: 29 September 2020
© The Author(s) 2020

Abstract

Purpose Drains' role after pancreaticoduodenectomy (PD) is debated by proponents of no drain, draining selected cases, and early drain removal. The aim of the study was to assess the effect of "standard" and "draining-tract-targeted" management of abdominal drains still in situ after diagnosing a postoperative pancreatic fistula (POPF).

Methods PubMed and Scopus were searched for "pancreaticoduodenectomy or pancreatoduodenectomy or duodenopancreatectomy," "Whipple," "proximal pancreatectomy," "pylorus-preserving pancreatectomy," and "postoperative pancreatic fistula or POPF." Main outcomes included clinically relevant (CR) POPF, grade-C POPF, overall mortality, POPF-related mortality, and CR-POPF-related mortality. Secondary outcomes were incidence of radiological and/or endoscopic interventions, reoperations, and completion pancreatectomies.

Results Overall, 12,089 studies were retrieved by the search of the English literature (01/01/1990–31/12/2018). Three hundred and twenty-six studies (90,321 patients) reporting ≥ 100 PDs and ≥ 10 PD/year were finally included into the study. Average incidences were obtained by averaging the incidence rates reported in the single articles. Pooled incidences were calculated by combining the number of events and the total number of patients considered in the various studies. These were then meta-analyzed using DerSimonian and Laird's (1986) method. Pearson's chi-squared test was used to compare pooled incidences between groups. Post hoc testing was used to see which groups differed. The meta-analyzed incidences were compared using a fixed effect for moderators. "Draining-tract-targeted" management showed a significant advantage over "standard" management in four clinically relevant outcomes out of eight according to pool analysis and in one of them according to meta-analysis.

Conclusion Clinically, "draining-targeted" management of POPF should be preferred to "standard" management.

Keywords Pancreas · Pancreatic surgery · Pancreaticoduodenectomy · Duodenopancreatectomy · Surgical drains · Pancreatic fistula

Introduction

Pancreatoduodenectomy (PD) has become safer over the past two decades, but POPF and its severe complications are still responsible for a significant perioperative mortality rate (approximately 1%) and quite a high morbidity rate (66–73%) [1–3].

Several different approaches have been used in efforts to mitigate the impact of POPFs, like different variants of pancreatic anastomosis [4–6], the use of fibrin and acrylic glues [7, 8] of the hormone somatostatin, or its synthetic analogs (SA) [9, 10] of internal or external stents [2, 11–13]. Placing drains during pancreatic surgery is a common strategy for preventing fluid accumulations and their infection, to mitigate POPF-related complications and to facilitate the detection of other intra-abdominal

Both authors meet all four criteria for authorship stated by the guidelines of the International Committee of Medical Journal Editors (ICMJE).

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00423-020-02005-8>) contains supplementary material, which is available to authorized users.

✉ Sergio Pedrazzoli
sergio.pedrazzoli@unipd.it

¹ Università degli Studi di Padova, Via Crescini, 39, 35126 Padua, Italy

² Dipartimento di Scienze Statistiche, Università degli Studi di Padova, Padua, Italy

48 complications, including hemorrhage [14, 15]. But abdominal
 49 drains can be responsible for the retrograde infection, hollow
 50 viscus decubitus, pain, discomfort, foreign body reaction, and
 51 prolonged hospital stays [16]. Drains generate considerable neg-
 52 ative pressure potentially responsible for the formation of POPFs
 53 [17]. Debate on the real usefulness of surgical drains was trig-
 54 gered by Jeekel [18] in 1992. Subsequent prospective random-
 55 ized trials designed to compare patients with and without drains
 56 after pancreatic surgery produced contradictory findings [19, 20].
 57 Several systematic reviews and meta-analyses have since been
 58 performed on this issue [21–30]. Unfortunately, the level of ev-
 59 idence for all the above-mentioned studies was moderate, low, or
 60 very low [29, 30].

61 Prophylactic drain placement during surgery is part of the
 62 “standard” management in order to avoid POPF [31].
 63 Unfortunately, even with drains, the clinical burden of a
 64 POPF may be significant.

65 An important advance for the purposes of assessing the
 66 efficacy of different mitigating procedures on the number
 67 and severity of POPFs came with the international classifica-
 68 tion of fistulae [32, 33]. Early recognition of a POPF in its
 69 harmless state of biochemical leak might help to reduce the
 70 risk of subsequent life-threatening complications [34].

71 The “standard” management of a POPF included maintain-
 72 ing drains in situ or gradually withdrawn and any further treat-
 73 ment was started only after there was a documented fluid
 74 collection and/or abscess. First-line management involved
 75 non-surgical options (percutaneous and/or endoscopic and/or
 76 endovascular treatment) whenever possible, followed by sur-
 77 gical treatment in the event of failure (Fig. 1) [35, 36]. None of
 78 the studies included in the previously mentioned systematic
 79 reviews examined the feasibility of a different approach to
 80 drain management, after a POPF has been diagnosed, to pre-
 81 vent it from developing into a CR-POPF and causing poten-
 82 tially life-threatening complications.

83 A “draining-tract-targeted” management of a POPF was
 84 proposed by some authors [37–39] and included starting the
 85 management as soon as possible after the diagnosis of a POPF
 86 to try preventing its harmful evolution. The drain’s path was
 87 used to study the fistula by means of a fistulography, to drain
 88 any fluid collections and, possibly, to perform a continuous
 89 washing of the fistula (Fig. 1).

90 The present review was aimed at assessing all the different
 91 approaches for managing surgical drains after a POPF has
 92 been diagnosed, in an effort to identify the best option (if
 93 any), capable of reducing the impact of POPFs on patients’
 94 postoperative course [38–40].

95 Methods

96 A previously considered corpus of 208 studies published from
 97 January 1, 1990, to December 31, 2015, on the morbidity and

mortality rates after pancreaticoduodenectomy in 60,739 pa- 98
 tients [2] was retrieved. Then, a comprehensive, systematic 99
 literature search was run in PubMed (Medline) and Scopus 100
 to identify further studies published from January 1, 2016, to 101
 December 31, 2018 (including articles published electronical- 102
 ly ahead of print). The search terms were 103
 “pancreaticoduodenectomy or pancreatoduodenectomy or 104
 duodenopancreatectomy,” “Whipple,” “proximal pancreatec- 105
 tomy,” “pylorus-preserving pancreatectomy,” and “postoper- 106
 ative pancreatic fistula or POPF.” Additional references were 107
 sought by cross-checking the bibliographies of the full-text 108
 articles selected according to the inclusion criteria. All causes 109
 for a proximal pancreatectomy, for both malignant and benign 110
 diseases, were included. Series containing only cases of 111
 chronic pancreatitis and/or trauma were excluded. 112

Inclusion and exclusion criteria 113


Published studies were included if (1) they were case-control 114
 studies, cohort studies, or randomized controlled trials (RCTs) 115
 published in the English language in peer-reviewed journals; 116
 (2) clearly defined pathology procedures (for benign or ma- 117
 lignant pancreatic lesions), and surgical procedures had been 118
 used; and (3) they included at least 100 PDs performed at 119
 centers handling at least 10 procedures a year, to avoid any 120
 bias associated with limited experience. Although a minimum 121
 of 10 PDs/year is no longer enough to define a center as “high- 122
 volume” [3], this threshold was retained to avoid discrepan- 123
 cies between the two periods considered in the review (1990– 124
 2015 and 2016–2018). 125

Publications were excluded if (1) they failed to meet any of 126
 the above-mentioned criteria; (2) they involved studies 127
 reporting partially or wholly duplicated data on patients de- 128
 scribed in previously published works; (3) they concerned 129
 studies focusing exclusively on laparoscopic surgery; or (4) 130
 they were reviews, editorials, expert opinions, case reports, or 131
 letters to the editor, not containing the authors’ data. 132

Statistical analysis 133

Averaged incidences were obtained by averaging the inci- 134
 dence rates reported in the single articles. Pooled incidences 135
 were calculated by combining the number of events and the 136
 total number of patients considered in the various studies. 137
 Pearson’s chi-squared test was used to compare incidences 138
 between groups. Post hoc testing based on Tukey contrasts 139
 was used to see which groups differed from each other. 140
 Averaged incidences were furthermore meta-analyzed using 141
 a random effects model according to DerSimonian and Laird’s 142
 (1986) method. Differences between the summary estimates 143
 were tested using a fixed effects moderator model. A signifi- 144
 cance level of 0.05 was set, below which *P* values were con- 145
 sidered statistically significant. All statistical analyses were 146

Fig. 1 Flow chart of the management of a POPF according to “standard” and “draining-tract-targeted” management of surgical drains



147 carried out using R version 3.6.2 (2019-12-12)—copyright
 148 (C) 2019, the R Foundation for Statistical Computing. In par-
 149 ticular, the metaphor package was used for meta-analysis.

150 Analysis of postoperative drain management

151 Unfortunately, the quality of reporting on PO drain manage-
 152 ment and perioperative data varied considerably in the publi-
 153 cations considered, so they were grouped on the grounds of
 154 completeness of reporting on POPF diagnosis and grading
 155 [32, 33], management of PO abdominal drains up until their
 156 removal, and percutaneous, endoscopic, or surgical manage-
 157 ment of POPF-related complications.

158 This led to the following groups and *subgroups*.

159 *Group A* included studies adequately reporting (i)
 160 details of the POPF diagnostic criteria [32, 33],
 161 and drain management after the POPF was diag-
 162 nosed; (ii) details of percutaneous/endoscopic drain-
 163 age and/or surgical management of POPF-related

164 complications, including completion pancreatectom-
 165 ies; in patients in *subgroup A1* (“standard” drain
 166 management), drains were left in place, or gradually
 167 retrieved, until resolution of POPF; in patients in
 168 *subgroup A2* (“draining-tract-targeted” manage-
 169 ment), drains were replaced under fluoroscopic con-
 170 trol and/or treated with lavage.

171 *Group B* included studies inadequately reporting the de-
 172 tails listed in the above item (ii), and patients were divid-
 173 ed into *subgroup B1* and *subgroup B2* according to their
 174 drain management, as above.

175 *Group C* included studies inadequately reporting the de-
 176 tails listed in both the above items (i) and (ii).

177 When considering the characteristics of the studies and the
 178 main outcomes, *subgroups A1* and *B1* were then pooled to-
 179 gether in *group A1-B1*, and *subgroups A2* and *B2* were pooled
 180 together in *group A2-B2*, while only *subgroups A1* and *A2*
 181 (the only ones with adequate data) were considered in terms
 182 of the secondary outcomes.

183 Main outcomes and measures

184 The main outcomes were CR-POPF rate (i.e., POPFs graded
185 as B/C), grade-C POPFs, overall PO mortality rate, overall
186 POPF-related mortality rate, and grade B/C POPF mortality
187 rate. For studies published before the publication of ISGPF
188 declarations [32], all symptomatic fistulas were considered
189 CR-POPF to compare the results of all CR-POPF thus obtain-
190 ed with those diagnosed only according to ISGPF criteria [32].
191 Secondary outcomes concerned the incidence of radiological
192 and/or endoscopic interventions, reoperations, and completion
193 pancreatectomies.

194 Results

195 In all, 4129 studies were retrieved from the major databases.
196 After removing 1347 duplicates and excluding 2589 studies
197 that did not meet our inclusion criteria, the full texts of the
198 remaining 193 studies were retrieved. An additional 42 studies
199 were identified by cross-checking the bibliographies of these
200 193 full-text articles. Then, 114 studies were omitted because
201 they were inconsistent with our inclusion criteria and another
202 3 because the full texts were unavailable (Fig. 2). The remain-
203 ing 118 studies, together with 208 studies selected previously,
204 [2] gave us a population of 90,321 patients considered in the
205 present review.

206 The studies were then divided into three groups according
207 to our previously explained criteria (group A1-B1; group A2-
208 B2; group C; Figure 3, Table 1). One of the more recent
209 studies was included in *subgroups A1* and *A2* because it cov-
210 ered the different types of surgical drain management, giving a
211 total of 327 instead of 326 studies. Group A1-B1 included 159
212 studies (37,489 patients), group A2-B2 included 20 studies
213 (5037 patients), and group C included 148 studies (47,795

214 patients). A Whipple procedure was reportedly used in 214
37,170 patients and a pylorus-preserving PD (PPPD) in 215
21,819, while no data were available for 31,332 patients 216
(34.69%). The distribution of Whipple procedures and 217
PPPD differed significantly between the three groups 218
(Whipple: 57.40%, 73.45%, and 67.06%; PPPD: 42.60%, 219
26.55%, and 32.94%, respectively; $P < 0.001$). A PJ or PG 220
was performed in 67,573 and 8987 patients, respectively, 221
while no data were available for 13,761 patients (15.24%). 222
The distribution of PJ and PG also differed significantly be- 223
tween the three groups (PJ: 85.22%, 83.86%, and 91.35%; 224
PG: 14.78%, 16.14%, and 8.65%; $P < 0.001$). An internal or 225
external stent was used in 17,026 and 11,780 patients, respec- 226
tively, while no stent was used in 29,441 patients, and no data 227
were available for 32,074 patients (35.51%). The proportional 228
usage of internal or external stents, or no stents differed sig- 229
nificantly between the three groups too (internal: 33.36%, 230
24.00%, and 26.00%; external: 13.45%, 17.34%, and 231
27.58%; no stents: 53.19%, 58.66%, and 46.42%: 232
 $P < 0.001$). Closed suction or passive drainage types of surgi- 233
cal drain were used in 11,373 and 59,674 patients, respective- 234
ly; no drain was used in 1029 patients, and no data were 235
available for 18,245 patients (20.20%). The proportions of 236
patients managed with closed suction or passive drainage so- 237
lutions, or no drains differed significantly between the three 238
groups (closed suction: 16.77%, 45.42%, and 9.73%; passive 239
drainage: 81.54%, 54.58%, and 88.91%; no drain: 1.69%, 0%, 240
and 1.36%; $P < 0.001$). Fibrin glue was used in 2322 patients 241
to strengthen the pancreatico-enteric anastomosis; no glue was 242
used in 48,326 patients, and no data were available for 39,673 243
patients (43.92%). The distribution of fibrin glue usage be- 244
tween the three groups differed significantly (with glue: 245
1.79%, 3.66%, and 8.08%; without glue: 98.21%, 96.34%, 246
and 91.92%; $P < 0.001$). Postoperatively, 14,692 patients 247
were given somatostatin or SA, 34,343 were not and no data 248

Fig. 2 Flow chart of study selection in a systematic review





Fig. 3 Flow chart of study division into groups and subgroups in relation to the adequacy of the information on diagnostic criteria of POPF, abdominal drains management after the diagnosis of POPF, percutaneous/endoscopic drainage, and/or surgical management of complications related to POPF completion pancreatectomies included. *Patients in one group A study were shared between subgroups A1 and A2 depending on their postoperative surgical drain management



249 were available for 41,286 patients (45.71%). The distribution
 250 of the perioperative somatostatin or SA administration dif-
 251 fered significantly between the three groups (38.90%,
 252 26.69%, and 20.58% were given the hormone; 61.10%,
 253 73.31%, and 79.42% were not; $P < 0.001$).

254 **Main outcomes**

255 The results observed in the three groups of patients, consider-
 256 ing for CR-POPFs, only those studies reporting ISGPF/ISGPS
 257 classifications [32, 33], are given in Table 2. The overall inci-
 258 dence of CR-POPFs was reported in 237 studies (72.48%)
 259 describing 63,921 of 90,321 patients (70.77%). The pooled

incidence of CR-POPFs was 13.33% and was significantly
 higher in group A2-B2 ($P = 0.009$), while the DL incidence
 was 12.56% without any significant difference between the
 three groups ($P = 0.498$). The overall incidence of grade-C
 POPFs was only reported by 193 studies (59.02%) describing
 54,241 patients (60.05%). Their pooled incidence was 3.45%
 and was significantly lower in group A2-B2 than in groups
 A1-B1 and C ($P = 0.001$); the DL incidence was 3.27% and
 was lower in group A2-B2 than in groups A1-B1 and C but
 the difference was not significant ($P = 0.091$). The overall PO
 mortality rate was reported in 296 studies (90.52%) describing
 76,743 patients (84.97%). The pooled incidence was 2.54%
 and was significantly higher for group C ($P = 0.007$). The DL

260
261
262
263
264
265
266
267
268
269
270
271
272

Q4

Table 1 Characteristics of groups A1-B1, A2-B2, and C and the sample overall

Characteristics	Group A1-B1	Group A2-B2	Group C	Overall	<i>P</i>
Studies (n.)	159 ^a	20 ^a	148	327 ^a	
Patients (n.)	37,489	5037	47,795	90,321	
Mean	235.78	251.85	322.94	276.21	
SD ^b	175.87	136.92	484.48	351.78	
Procedures (n.):					
Whipple	15,873	3231	18,066	37,170	< 0.001
PPPD ^c	11,778	1168	8873	21,819	
Not reported	9838	638	20,856	31,332	
Studies without data	36	1	41	78	
Pancreatic anastomosis (n.)					
PJ ^d	28,151	3787	35,635	67,573	< 0.001
PG ^e	4883	729	3375	8987	
Not reported	4455	521	8785	13,761	
Studies without data	17	2	33	52	
Stents (n.):					
Internal	8959	1148	6919	17,026	< 0.001
External	3613	829	7338	11,780	
None	14,284	2805	12,352	29,441	
Not reported	10,633	255	21,186	32,074	
Studies without data	40	2	55	97	
Drains (n.):					
Closed suction	6100	2288	2985	11,373	< 0.001
Passive drainage	29,656	2749	27,269	59,674	
None	613	0	416	1029	
Not reported	1120	0	17,125	18,245	
Studies without data	6	0	40	46	
Fibrin glue:					
Used	458	128	1736	2322	< 0.001
Not used	25,193	3374	19,759	48,326	
Not reported	11,838	1535	26,300	39,673	
Studies without data	49	6	80	133	
Somatostatin or analogs:					
Used	9341	880	4471	14,692	< 0.001
Not used	14,669	2417	17,257	34,343	
Not reported	13,479	1740	26,067	41,286	
Studies without data	48	6	73	127	

^a Patients in one study were shared between *subgroups* A1 and A2 depending on their postoperative surgical drain management

^b Standard deviation

^c Pylorus-preserving pancreaticoduodenectomy

^d Pancreaticojejunostomy

^e Pancreaticogastrostomy

273 incidence was 2.54% without any significant difference be- 280
 274 tween the three groups ($P = 0.187$). The overall POPF-related 281
 275 mortality was reported in 268 studies (81.96%) describing 282
 276 74,437 patients (82.41%). The pooled POPF-related mortality 283
 277 was 1.06% and was significantly lower in group A2-B2 than 284
 278 in groups A1-B1 and C ($P = 0.004$). The DL incidence of 285
 279 POPF-related mortality was 1.23% and was lower in group 286

A2-B2 than in groups A1-B1 and C but the difference was not 280
 significant ($P = 0.088$). The CR-POPF-related mortality was 281
 reported in 180 studies (55.05%) reporting 6594 CR-POPFs 282
 among 49,319 patients (13.37%). The pooled incidence was 283
 7.28% and the DL incidence was 8.88%; the lowest incidence 284
 found for group A2-B2 was not statistically significant ($P =$ 285
 0.083 and $= 0.245$, respectively). 286

Table 2 Results for primary endpoints in groups A1-B1, A2-B2, and C, and the sample overall

Primary endpoints	Group A1-B1	Group A2-B2	Group C	Overall	<i>P</i>
CR-POPF ^a					
Studies	119/159	16/20	102/148	237/327 ^d	
Patients	25,794	3663	34,464	63,921	
Mean	216.76	228.94	337.88	269.71	
SD ^b	154.99	126.99	500.61	351.88	
Average incidence (%)	13.38	14.24	14.35	13.90	
SD ^b	8.21	10.89	8.18	8.38	
Pooled incidence (%)	12.91	14.50	13.53	13.33	= 0.009
DL incidence ^c (%)	12.08	13.95	13.18	12.56	= 0.498
Grade-C POPF					
Studies	103/159	14/20	76/148	193/327 ^d	
Patients	23,264	3622	27,355	54,241	
Mean	225.86	258.71	359.93	281.04	
SD ^b	160.58	132.94	561.25	376.93	
Average incidence (%)	3.77	2.36	3.91	3.72	
SD ^b	4.61	2.39	3.16	3.97	
Pooled incidence (%)	3.63	2.15	3.48	3.45	= 0.001
DL incidence ^c (%)	3.18	2.11	3.58	3.27	= 0.091
Overall PO mortality					
Studies	148/159	20/20	128/148	296/327 ^d	
Patients	33,795	5037	37,911	76,743	
Mean	228.35	251.85	296.18	259.27	
SD ^b	174.44	136.92	427.85	310.25	
Average incidence (%)	2.26	2.51	2.74	2.49	
SD ^b	2.11	2.24	2.66	2.37	
Pooled incidence (%)	2.37	2.30	2.72	2.54	= 0.007
DL incidence ^c (%)	2.33	2.49	2.78	2.54	= 0.187
POPF-related mortality					
Studies	147/159	18/20	103/148	268/327 ^d	
Patients	34,098	4762	35,577	74,437	
Mean	231.96	264.56	345.41	277.75	
SD ^b	173.20	138.54	563.65	376.73	
Average incidence (%)	1.03	0.49	1.21	1.07	
SD ^b	1.37	0.63	1.49	1.39	
Pooled incidence (%)	1.04	0.61	1.14	1.06	= 0.004
DL incidence ^c (%)	1.25	0.79	1.30	1.23	= 0.088
CR-POPF ^a -related mortality					
Studies	108/159	14/20	60/148	180/327 ^d	
Patients with CR-POPF	2891	501	3202	6594	
Mean	26.77	35.79	51.65	35.84	
SD ^b	25.27	35.29	71.45	47.93	
Average incidence (%)	8.27	5.00	9.13	8.31	
SD ^b	11.42	7.84	11.98	11.38	
Pooled incidence (%)	7.47	4.79	7.50	7.28	= 0.083
DL incidence ^c (%)	9.73	5.65	8.45	8.88	= 0.245

^a For CR-POPFs, only those studies reporting ISGPF/ISGPS classifications [32, 33] were considered

^b Standard deviation

^c DL incidence (%): DerSimonian-Laird estimator

^d Patients in one study were shared between *subgroups* A1 and A2 depending on their postoperative surgical drain management

287 If we consider all patients with CR-POPF (both those defined on the basis of the ISGPF/ISGPS classifications [32, 33] and the symptomatic ones reported in studies published before the publication of the ISGPF criteria), the results were similar to those reported in Table 2 for the pooled incidence and DL incidence of CR-POPFs ($P = 0.009$ and 0.699 , respectively) while for the CR-POPF-related mortality, the lowest incidence detected for the A2-B2 group became statistically significant for the pooled incidence and remained not significant for the

DL incidence ($P = 0.031$ and 0.090 , respectively) (see Table 4 in the electronic supplemental material). 296 297

Secondary outcomes 298

The results of group A studies are reported in Table 3. Concerning the overall incidence of radiological/endoscopic interventions, which was reported in 96/109 group A studies (88.07%), the pooled incidence was 4.14% and the DL 302

Table 3 Results for secondary endpoints in group A and subgroups A1 and A2

	Secondary endpoints	Subgroup A1	Subgroup A2	Group A	<i>P</i>
t3.3	Studies (n.)	93 ^b	16 ^b	109	
t3.4	Patients (n.)	22,299	4179	26,478	
t3.5	Mean	239.77	261.19	242.92	
t3.6	SD ^a	168.00	136.02	163.31	
t3.7	Interventions ^c				
t3.8	Studies	82	14	96	
t3.9	Patients	19,418	3703	23,121	
t3.10	Mean	236.80	264.50	240.84	
t3.11	SD ^a	165.82	134.24	161.27	
t3.12	Average incidence (%)	4.47	4.61	4.49	
t3.13	SD ^a	4.66	3.59	4.50	
t3.14	Pooled incidence (%)	4.03	4.73	4.14	= 0.058
t3.15	DL incidence ^d (%)	3.67	3.94	3.82	= 0.123
t3.16	Reoperations				
t3.17	Studies	92	16	108	
t3.18	Patients	22,198	4179	26,377	
t3.19	Mean	241.28	261.19	244.23	
t3.20	SD ^a	168.28	136.02	163.49	
t3.21	Average incidence (%)	3.92	2.32	3.68	
t3.22	SD ^a	3.78	2.50	3.65	
t3.23	Pooled incidence (%)	3.93	2.25	3.66	< 0.001
t3.24	DL incidence ^d (%)	3.26	2.04	3.04	= 0.069
t3.25	Completion pancreatectomies				
t3.26	Studies	83	16	99	
t3.27	Patients	20,261	4179	24,440	
t3.28	Mean	244.11	261.19	246.87	
t3.29	SD ^a	170.67	136.02	165.06	
t3.30	Average incidence (%)	0.56	0	0.47	
t3.31	SD ^a	1.22	0	1.14	
t3.32	Pooled incidence (%)	0.65	0	0.54	< 0.001
t3.33	DL incidence ^d (%)	0.67	0.22	0.57	= 0.004

^a Standard deviation

^b Patients of one study were divided between subgroups A1 and A2 according to the PO management of surgical drains

^c POPF-related radiological/endoscopic interventions

^d DL incidence (%): DerSimonian-Laird estimator

303 incidence was 3.82%, without any significant differences be- 315
 304 tween the two subgroups A1 and A2 ($P = 0.058$ and 0.123 , 316
 305 respectively). The overall reoperation rate was reported in 317
 306 108/109 group A studies (99.08%). The pooled incidence of 318
 307 reoperation rate was 3.66% and was significantly lower in 319
 308 subgroup A2 than in subgroup A1 ($P < 0.001$). The DL inci-
 309 dence was 3.04%, and the lowest incidence found for
 310 subgroup A2 than in subgroup A1 was not statistically signif-
 311 icant (0.069%). The overall completion pancreatectomy rate
 312 was reported in 99/109 group A studies (90.83%) giving a
 313 pooled incidence of 0.54% and a DL incidence of 0.57%.
 314 The incidence of completion pancreatectomy was

significantly lower in subgroup A2 than in subgroup A1 ac-
 cording to both the pooled analysis ($P < 0.001$) and to meta-
 analysis ($P = 0.004$).

Forest plots of the primary and secondary outcomes are
 reported in the [electronic supplemental material](#).

Discussion

This comprehensive systematic review pooled analysis and
 meta-analysis of 326 studies published between January 1,
 1990, and December 31, 2018, (referring to 91,321 patients)

324 is the first large review on the management of surgical drains
 325 still in situ after a POPF is diagnosed in patients undergoing
 326 PD. The main finding was a better result in four clinically
 327 relevant outcomes considered (grade-C POPFs; POPF-
 328 related mortality rate; reoperations; and completion pan-
 329 createctomies) that was statistically significant in all four accord-
 330 ing to the pooled analysis and only in one (completion pan-
 331 createctomies) according to the meta-analysis, in patients who
 332 underwent “draining-tract-targeted” (group A2-B2 in Table 2;
 333 subgroup A2 in Table 3) than in those undergoing “standard”
 334 drain management (groups A1-B1 and C in Table 2; subgroup
 335 A1 in Table 3).

336 Given that an improvement close to significance was also
 337 obtained in the three relevant non-significant outcomes at the
 338 meta-analysis (grade-C POPF: $P = 0.091$; POPF-related mortal-
 339 ity: $P = 0.088$; reoperations: $P = 0.069$; Tables 2 and 3) and
 340 that the large and very heterogeneous number of studies in-
 341 cluded in this review is better analyzed by an aggregate anal-
 342 ysis than by a meta-analysis, we believe the improvement of
 343 the four outcomes observed in patients treated with “draining-
 344 tract-targeted” management is clinically relevant.

345 The increase in CR-POPF and the decrease in overall
 346 PO mortality in patients undergoing “drainage-targeted”
 347 management (significant only according to the pooled
 348 analysis: $P = 0.009$ and $= 0.007$) were not included
 349 among the clinically relevant outcomes due to the frank-
 350 ly negative results of the meta-analysis (Table 2). The
 351 lower pooled and DL incidence of CR-POPF-related
 352 mortality in patients undergoing “draining-tract-targeted”
 353 management was not significant; the result could be
 354 explained by the smaller number of studies reporting
 355 this information (180/327 only, Table 2). Finally, there
 356 were no significant differences in the pooled and DL
 357 incidence of interventions between the three groups of
 358 patients (Table 3) confirming that “draining-tract-
 359 targeted” management does not exclude the possibility
 360 of subsequent interventions (Fig. 1).

361 These interesting results, although not univocal, emerged
 362 despite the relatively small number of studies in group A2-B2
 363 compared with those in groups A1-B1 and C, and despite the
 364 lack of homogeneity in the “draining-tract-targeted” man-
 365 agement adopted for group A2-B2 [37–39]. Furthermore, com-
 366 paring the results of the CR-POPFs defined on the basis of the
 367 ISGPF/ISGPS classifications [32, 33] (Table 2) with those of
 368 CR-POPFs which also included the symptomatic ones report-
 369 ed prior to publication of the ISGPF criteria, the results of the
 370 pooled and DL incidence of CR-POPF ($P = 0.009$ and
 371 $P = 0.923$) were similar, while the lowest incidence of
 372 CR-POPF-related mortality of group A2-B2 than groups
 373 A1-B1 and C became statistically significant for the
 374 pooled incidence ($P = 0.031$) and remained not signifi-
 375 cant for the DL incidence ($P = 0.261$) (see Table 4 in
 376 the electronic supplemental material).

377 During the 28 years of this review, only 179/326 studies
 378 (54.91%) reported the surgical drain management after diag-
 379 nosing a POPF with a prevalent use of “standard” drain man-
 380 agement (159/179 studies, 88.83%), compared to “draining-
 381 tract-targeted” management (20 studies, 11.17%). In the for-
 382 mer “standard” case, the drain was left in place or gradually
 383 withdrawn, and any further treatment was started only after a
 384 CR-POPF was diagnosed and there was a documented fluid
 385 collection and/or abscess (Fig. 1). [34, 41–44] In the
 386 “draining-tract-targeted” management of POPFs, treatment
 387 was started as soon as possible after diagnosing a POPF to
 388 reduce the risk of subsequent life-threatening complications
 389 (Fig. 1) [34]. “Draining-tract-targeted” management included
 390 three different approaches: (1) fistulography through the sur-
 391 gical drains with their subsequent replacement, or reposi-
 392 tioning, over a wire [37]; (2) drain replacement with some
 393 pigtail or malecot 8–10 Fr one of which was inserted as soon
 394 as possible through the fistula into the gastrointestinal lumen
 395 [38, 45, 46]; (3) drain replacement under fluoroscopic control
 396 and closed lavage with 500 to 3000 mL of natural saline de-
 397 pending on the amylase level in the drained fluid [39]. It is
 398 worth emphasizing that using “draining-tract-targeted” man-
 399 agement did not prevent subsequent use of percutaneous and/
 400 or endoscopic drainage of any fluid collections or abscesses
 401 (Fig. 1) (Table 3); these procedures have technical success
 402 rates of 100% and 92–97%, respectively, but clinical success
 403 rates of only 67–77% and 59%, respectively. [36, 47, 48]
 404 Postoperative infections are a major determinant of outcome
 405 after PD [49, 50], and drain lavage and/or replacement can
 406 also help to reduce PO intra-abdominal infection. The earlier
 407 and easier approach to POPF treatment by “draining-tract-
 408 targeted” management can help explain the different out-
 409 comes of the two approaches.

410 According to Tomimaru et al. [51] fistulography findings
 411 were significantly associated with POPF healing time. An
 412 intra-abdominal drainage tube was changed every 1–
 413 2 weeks until the POPF is resolved. A “draining-tract-
 414 targeted” management of biochemical leakage (BL) was also
 415 proposed by Takeda et al. [52] A fistulography was performed
 416 weekly, starting on POD 7. The surgical drain was replaced
 417 with an 8-Fr soft drain. The weekly routine fistulography was
 418 not considered as an interventional procedure because it had
 419 only a diagnostic purpose, whereas any additional
 420 fistulography and repositioning of drains due to signs of in-
 421 fection were considered as percutaneous intervention therapy.
 422 This distinction poses the problem of how to frame the differ-
 423 ent “draining-tract-targeted” managements of POPFs [37–39,
 424 51, 52] in the ISGPF/ISGPS classifications [32, 33].

425 In a previous review [2], we reported a POPF-related mor-
 426 tality rate of around 1%, which had remained unchanged over
 427 a 25-year study period. This rate increased significantly—to
 428 1.2% ($P = 0.007$)—during the last 3 years covered by the
 429 present review. We can therefore assume that, during the last

430 28 years, the prevalent treatment of a POPF (“standard”
431 drain management) has not changed the POPF-related
432 mortality rate.

433 Routinely placing intraperitoneal drains after PD was con-
434 sidered a strategy to mitigate the incidence and effects of
435 POPFs. In our present study, 98.57% of the patients with
436 adequate data available on the use of drains had a drain placed
437 at the end of the surgical procedure, and the rate was the same
438 for the patients reported in studies published in the last 3 years
439 (23,533 out of 23,951 patients; 98.25%). Unfortunately, 46
440 studies (14.11%) failed to report on the type of drainage treat-
441 ment after surgery (Table 1), and 22 of them were published in
442 the last 3 years (22/118—18.64%).

443 After the actual usefulness of abdominal drains was called
444 into question for other abdominal surgeries [53–55] and for
445 pancreatic surgery [18], there has been a great debate among
446 the drainers [20] non-drainers [19, 56], selective drainers ac-
447 cording to the Fistula Risk Score [57–59], the early drain
448 removers [16, 60], and selective drainers and early removers
449 [61]. Several systematic reviews and meta-analyses that vari-
450 ously included both RCTs and non-RCTs, both on PD and
451 distal pancreatectomy [21–30], led to different opinions re-
452 garding the usefulness of drains after PD. Some judged them
453 demonstrably useful [23, 27, 30], while others found no evi-
454 dence to confirm as much [28, 29]. Some said they are only
455 useful in selected patients (such as those at high risk of POPF)
456 [25]. Other findings were neutral (drains neither increased nor
457 reduced PO complications and mortality) [21, 22, 24, 26].
458 When drains were used, their early removal seemed a good
459 idea [21, 24, 29, 30]. Unfortunately, the level of evi-
460 dence for all the above-mentioned studies was moderate,
461 low, or very low [29, 30].

462 According to McMillan’s study [61], drains can be safely
463 omitted for one in four patients undergoing PD and removed
464 early in a sizable proportion of cases. Drains would nonethe-
465 less remain in place after diagnosing a POPF in at least 20.4%
466 of patients. A similar experience was reported by Trudeau
467 et al. [62]. Drains remained in place in 12.75% of patients,
468 the overall CR-POPF rate was 8.7%, and the overall mortality
469 rate was .8%, almost all in patients with CR-POPFs and sur-
470 gical drains still in place. Therefore, drains remain in
471 place in a relevant percentage of POPFs, and their best
472 treatment is still undefined.

473 POPF-related mortality rate was reported only in 268 out of
474 326 studies (82.21%), but only in 61 out of 118 studies
475 (51.69%) of the more recent period (2016–2018). We believe
476 that POPF-related mortality rate is a very important objective
477 parameter to be evaluated, at least as important as complica-
478 tion rate and hospital stay. Unfortunately, neither the
479 International Study Group on Pancreatic Surgery (ISGPS)
480 [33] nor 23 International Expert Centers in pancreas surgery
481 [3] included an accurate definition of POPF-related mortality
482 rate among the outcome parameters of pancreatic surgery.

483 An important limitation of our review lies in the retrospec-
484 tive analysis of mainly retrospective studies and the large gaps
485 in the reporting of the data as evidenced in Tables 1, 2, and 3.
486 The number of studies and patients with missing data for each
487 characteristic and outcome is indicated in the tables. Complete
488 datasets for all the variables required in Tables 1 and 2 were
489 only available in 67 of the 326 studies considered in this
490 review (20.55%)—and in none of the 118 studies published
491 between 2016 and 2018 (It is noteworthy that the ISGPF clas-
492 sification was reported in 98% of the latter studies). As for the
493 secondary outcomes, they were not only lacking in all 70
494 studies in group B and 148 studies in group C, but also miss-
495 ing in 9/93 studies in group A1 and 1/16 in group A2.

496 Another point to mention is that the clinically better out-
497 come for four out of eight outcomes in group A2-B2 and
498 *subgroup* A2 is important but needs to be confirmed in
499 RCTs because it emerged from retrospective studies without
500 enough detail concerning the distribution between the groups
501 of several non-modifiable risk factors (e.g., age, body mass
502 index, comorbidity, underlying diseases, gland texture, and
503 Wirsung duct size). There is also to consider that three differ-
504 ent types of “draining-tract-targeted” management were
505 adopted [37–39].

506 Conclusion

507 In conclusion, this review is focused on the management of
508 drains still in situ when a POPF is diagnosed. Instead of leav-
509 ing them in place, or gradually withdrawing them (as is usu-
510 ally done in the “standard” management approach), their pres-
511 ence can be usefully exploited both for a diagnostic
512 fistulography, to check for any collections communicating
513 with the drainage tract [38, 48], and for therapeutic purpose,
514 using any readily available method to replace or reposition
515 drains under fluoroscopic control and, where necessary, pro-
516 ceed with continuous lavage of the draining tract [37–39, 47,
517 48]. Compared with “standard” management, the use of a
518 “draining-tract-targeted” management approach achieved
519 clinically better results for four of the eight outcomes consid-
520 ered here.

521 **Acknowledgments** The authors would like to express their gratitude to
522 Dr. Luisa Banzato of the Biblioteca Pinali at the University of Padua for
523 the help with retrieving the papers included in this review.

524 **Funding** Open access funding provided by Università degli Studi di
525 Padova within the CRUI-CARE Agreement.

527 Compliance with ethical standards

528 **Conflict of interest** The authors declare that they have no conflict of
529 interest.

530 **Ethical approval** This article does not contain any studies with human
531 participants or animals performed by any of the authors.

532 **Open Access** This article is licensed under a Creative Commons
533 Attribution 4.0 International License, which permits use, sharing,
534 adaptation, distribution and reproduction in any medium or format, as
535 long as you give appropriate credit to the original author(s) and the
536 source, provide a link to the Creative Commons licence, and indicate if
537 changes were made. The images or other third party material in this article
538 are included in the article's Creative Commons licence, unless indicated
539 otherwise in a credit line to the material. If material is not included in the
540 article's Creative Commons licence and your intended use is not
541 permitted by statutory regulation or exceeds the permitted use, you will
542 need to obtain permission directly from the copyright holder. To view a
543 copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.
544

References

- 546 1. van Rijssen LB, Zwart MJ, van Dieren S, de Rooij T, Bonsing BA,
547 Bosscha K, van Dam RM, van Eijck CH, Gerhards MF, Gerritsen
548 JJ, van der Harst E, de Hingh IH, de Jong KP, Kazemier G, Klaase
549 J, van der Kolk BM, van Laarhoven CJ, Luyer MD, Molenaar IQ,
550 Patijn GA, Rupert CG, Scheepers JJ, van der Schelling GP,
551 Vahrmeijer AL, Busch ORC, van Santvoort HC, Groot
552 Koerkamp B, Besselink MG, Dutch Pancreatic Cancer Group
553 (2018) Variation in hospital mortality after pancreatoduodenectomy
554 is related to failure to rescue rather than major complications: a
555 nationwide audit. *HPB (Oxford)* 20:759–767
- 556 2. Pedrazzoli S (2017) Pancreatoduodenectomy (PD) and postopera-
557 tive pancreatic fistula (POPF): a systematic review and analysis of
558 the POPF-related mortality rate in 60,739 patients retrieved from
559 the English literature published between 1990 and 2015. *Medicine*
560 (Baltimore) 96:e6858
- 561 3. Sánchez-Velázquez P, Muller X, Malleo G, Park JS, Hwang HK,
562 Napoli N, Javed AA, Inoue Y, Beghdadi N, Kalisvaart M, Vigia E,
563 Walsh CD, Lovasik B, Busquets J, Scandavini C, Robin F,
564 Yoshitomi H, Mackay TM, Busch OR, Hartog H, Heinrich S,
565 Gleisner A, Perinel J, Passeri M, Lluis N, Raptis DA, Tschuor C,
566 Oberkofler CE, DeOliveira ML, Petrowsky H, Martinie J, Asbun H,
567 Adham M, Schulick R, Lang H, Koerkamp BG, Besselink MG,
568 Han HS, Miyazaki M, Ferrone CR, Fernández-Del Castillo C,
569 Lillemo KD, Sulpice L, Boudjema K, Del Chiaro M, Fabregat J,
570 Kooby DA, Allen P, Lavu H, Yeo CJ, Barroso E, Roberts K,
571 Muiesan P, Sauvanet A, Saiura A, Wolfgang CL, Cameron JL,
572 Boggi U, Yoon DS, Bassi C, Puhan MA, Clavien PA (2019)
573 Benchmarks in pancreatic surgery: a novel tool for unbiased out-
574 come comparisons. *Ann Surg* 270:211–218
- 575 4. Daamen LA, Smits FJ, Besselink MG, Busch OR, Borel Rinkes IH,
576 van Santvoort HC, Molenaar IQ, Dutch Pancreatic Cancer Group
577 (2018) A web-based overview, systematic review and meta-
578 analysis of pancreatic anastomosis techniques following
579 pancreatoduodenectomy. *HPB (Oxford)* 20:777–785
- 580 5. Hashimoto D, Chikamoto A, Ohmuraya M, Baba H (2014)
581 Pancreaticodigestive anastomosis and the postoperative manage-
582 ment strategies to prevent postoperative pancreatic fistula forma-
583 tion after pancreaticoduodenectomy. *Surg Today* 44:1207–1213
- 584 6. Wang W, Zhang Z, Gu C, Liu Q, Liang Z, He W (2018) The
585 optimal choice for pancreatic anastomosis after
586 pancreaticoduodenectomy: a network meta-analysis of randomized
587 control trials. *Int J Surg* 57:111–116
- 588 7. Orci LA, Oldani G, Berney T, Andres A, Mentha G, Morel P, Toso
589 C (2014) Systematic review and meta-analysis of fibrin sealants for
590 patients undergoing pancreatic resection. *HPB (Oxford)* 16:3–11
8. Gong J, He S, Cheng Y, Cheng N, Gong J, Zeng Z (2018) Fibrin
591 sealants for the prevention of postoperative pancreatic fistula fol-
592 lowing pancreatic surgery. *Cochrane Database Syst Rev* 6:
593 CD009621
9. Klempa I, Schwedes U, Usadel KH (1979) Prevention of postop-
594 erative pancreatic complications following
595 duodenopancreatectomy using somatostatin. *Chirurg* 50:427–431
10. Adiamah A, Arif Z, Berti F, Singh S, Laskar N, Gomez D (2019)
596 The use of prophylactic somatostatin therapy following
597 pancreaticoduodenectomy: a meta-analysis of randomised con-
598 trolled trials. *World J Surg* 43:1788–1801
11. Roder JD, Stein HJ, Böttcher KA, Busch R, Heidecke CD, Siewert
599 JR (1999) Stented versus nonstented pancreaticojejunostomy after
600 pancreatoduodenectomy: a prospective study. *Ann Surg* 229:41–48
12. Ecker BL, McMillan MT, Asbun HJ, Ball CG, Bassi C, Beane JD,
601 Behrman SW, Berger AC, Dickson EJ, Bloomston M, Callery MP,
602 Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong
603 ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB,
604 Javed AA, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Poruk
605 KE, Salem RR, Schmidt CR, Soares K, Stauffer JA, Valero V, LKP
606 V, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr
607 (2018) Characterization and optimal management of high-risk pan-
608 creatic anastomoses during pancreatoduodenectomy. *Ann Surg*
609 267:608–616
13. Nahm CB, Connor SJ, Samra JS, Mittal A (2018) Postoperative
610 pancreatic fistula: a review of traditional and emerging concepts.
611 *Clin Exp Gastroenterol* 11:105–118
14. Correa-Gallego C, Brennan MF, D'Angelica M, Fong Y, Dematteo
612 RP, Kingham TP, Jarnagin WR, Allen PJ (2013) Operative drain-
613 age following pancreatic resection: analysis of 1122 patients
614 resected over 5 years at a single institution. *Ann Surg* 258:1051–
615 1058
15. Cyr DP, Truong JL, Lam-McCulloch J, Cleary SP, Karanicolas PJ
616 (2015) Canadian practice patterns for pancreaticoduodenectomy.
617 *Can J Surg* 58:121–127
16. Bassi C, Molinari E, Malleo G, Crippa S, Butturini G, Salvia R,
618 Talamini G, Pederzoli P (2010) Early versus late drain removal after
619 standard pancreatic resections: results of a prospective randomized
620 trial. *Ann Surg* 252:207–214
17. Villafane-Ferriol N, Baugh KA, McElhany AL, Van Buren G 2nd,
621 Fang A, Tashakori EK, Reyes JEM, Cao HST, Silberfein EJ,
622 Massarweh N, Hsu C, Barakat O, Schmidt C, Zyromski NJ,
623 Dillhoff M, Villarreal JA, Fisher WE (2019) Evidence versus prac-
624 tice in early drain removal after pancreatectomy. *J Surg Res* 236:
625 332–339
18. Jeekel J (1992) No abdominal drainage after Whipple's procedure.
626 *Br J Surg* 79:182
19. Conlon KC, Labow D, Leung D, Smith A, Jarnagin W, Coit DG,
627 Merchant N, Brennan MF (2001) Prospective randomized clinical
628 trial of the value of intraperitoneal drainage after pancreatic resec-
629 tion. *Ann Surg* 234:487–493 discussion 493–494
20. Van Buren G 2nd, Bloomston M, Hughes SJ, Winter J, Behrman
630 SW, Zyromski NJ, Vollmer C, Velanovich V, Riall T, Muscarella
631 P, Trevino J, Nakeeb A, Schmidt CM, Behrns K, Ellison EC,
632 Barakat O, Perry KA, Drebin J, House M, Abdel-Misih S,
633 Silberfein EJ, Goldin S, Brown K, Mohammed S, Hodges SE,
634 McElhany A, Issazadeh M, Jo E, Mo Q, Fisher WE (2014) A
635 randomized prospective multicenter trial of
636 pancreaticoduodenectomy with and without routine intraperitoneal
637 drainage. *Ann Surg* 259:605–612
21. Diener MK, Tadjalli-Mehr K, Wente MN, Kieser M, Büchler MW,
638 Seiler CM (2011) Risk-benefit assessment of closed intra-
639 abdominal drains after pancreatic surgery: a systematic review
640 and meta-analysis assessing the current state of evidence. *Arch*
641 *Surg* 396:41–52

- 656 22. van der Wilt AA, Coolsen MM, de Hingh IH, van der Wilt GJ, 721
657 Groenewoud H, Dejong CH, van Dam RM (2013) To drain or 722
658 not to drain: a cumulative meta-analysis of the use of routine 723
659 abdominal drains after pancreatic resection. *HPB (Oxford)* 15:337– 724
660 344 725
- 661 23. Dou CW, Liu ZK, Jia YL, Zheng X, Tu KS, Yao YM, Liu QG 726
662 (2015) Systematic review and meta-analysis of prophylactic 727
663 abdominal drainage after pancreatic resection. *World J Gastroenterol* 728
664 21:5719–5734 729
- 665 24. Peng S, Cheng Y, Yang C, Lu J, Wu S, Zhou R, Cheng N (2015) 730
666 Prophylactic abdominal drainage for pancreatic surgery. *Cochrane* 731
667 *Database Syst Rev* 8:CD010583 732
- 668 25. Wang YC, Szatmary P, Zhu JQ, Xiong JJ, Huang W, Gomatos I, 733
669 Nunes QM, Sutton R, Liu XB (2015) Prophylactic intra-peritoneal 734
670 drain placement following pancreaticoduodenectomy: a systematic 735
671 review and meta-analysis. *World J Gastroenterol* 21:2510–2521 736
- 672 26. Hüttner FJ, Probst P, Knebel P, Strobel O, Hackert T, Ulrich A, 737
673 Büchler MW, Diener MK (2017) Meta-analysis of prophylactic 738
674 abdominal drainage in pancreatic surgery. *Br J Surg* 104:660–668 739
- 675 27. Huan L, Fei Q, Lin H, Wan L, Li Y (2017) Is peritoneal drainage 740
676 essential after pancreatic surgery? A meta-analysis and systematic 741
677 review. *Medicine (Baltimore)* 96:e9245 742
- 678 28. Schorn S, Nitsche U, Demir IE, Scheufele F, Tieftrunk E, Schirren 743
679 R, Klauss S, Sargut M, Ceyhan GO, Friess H (2018) The impact of 744
680 surgically placed, intraperitoneal drainage on morbidity and 745
681 mortality after pancreas resection- a systematic review & meta-analysis. 746
682 *Pancreatology* 18:334–345 747
- 683 29. Zhang W, He S, Cheng Y, Xia J, Lai M, Cheng N, Liu Z (2018) 748
684 Prophylactic abdominal drainage for pancreatic surgery. *Cochrane* 749
685 *Database Syst Rev* 6:CD010583 750
- 686 30. Villafane-Ferriol N, Shah RM, Mohammed S, Van Buren G 2nd, 751
687 Barakat O, Massarweh NN, Tran Cao HS, Silberfein EJ, Hsu C, 752
688 Fisher WE (2018) Evidence-based management of drains following 753
689 pancreatic resection: a systematic review. *Pancreas* 47:12–17 754
- 690 31. Linnemann RJA, Patijn GA, van Rijssen LB, Besselink MG, 755
691 Munroop TH, de Hingh IH, Kazemier G, Festen S, de Jong KP, 756
692 van Eijck CHJ, Scheepers JGG, van der Kolk M, Dulk MD, Bosscha 757
693 K, Busch OR, Boerma D, van der Harst E, Nieuwenhuijs VB, 758
694 Dutch Pancreatic Cancer Group (2019) The role of abdominal 759
695 drainage in pancreatic resection - a multicenter validation study 760
696 for early drain removal. *Pancreatology* 19:888–896 761
- 697 32. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, 762
698 Neoptolemos J, Sarr M, Traverso W, Buchler M, International 763
699 Study Group on Pancreatic Fistula Definition (2005) Postoperative 764
700 pancreatic fistula: an international study group 765
701 (ISGPF) definition. *Surgery* 138:8–13 766
- 702 33. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham 767
703 M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del 768
704 Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo 769
705 C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe 770
706 KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada 771
707 T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, 772
708 Salvia R, Buchler M, International Study Group on Pancreatic 773
709 Surgery (ISGPS) (2017) The 2016 update of the International 774
710 Study Group (ISGPS) definition and grading of postoperative pan- 775
711 creatic fistula: 11 years after. *Surgery* 161:584–591 776
- 712 34. Smits FJ, Molenaar IQ, Besselink MG, Borel Rinkes IHM, van 777
713 Eijck CHJ, Busch OR, van Santvoort HC, Dutch Pancreatic 778
714 Cancer Group (2020) Early recognition of clinically relevant post- 779
715 operative pancreatic fistula: a systematic review. *HPB (Oxford)* 22: 780
716 1–11 781
- 717 35. Beane JD, Borrebach JD, Zureikat AH, Kilbane EM, Thompson 782
718 VM, Pitt HA (2019) Optimal pancreatic surgery: are we making 783
719 progress in North America? *Ann Surg Publish Ahead of Print.* 784
720 <https://doi.org/10.1097/SLA.0000000000003628> 785
36. Smits FJ, van Santvoort HC, Besselink MG, Batenburg MCT, 721
Slooff RAE, Boerma D, Busch OR, Coene PPLO, van Dam RM, 722
van Dijk DPJ, van Eijck CHJ, Festen S, van der Harst E, de Hingh 723
IHJT, de Jong KP, Tol JAMG, Borel Rinkes IHM, Molenaar IQ, 724
Dutch Pancreatic Cancer Group (2017) Management of severe pan- 725
creatic fistula after pancreatoduodenectomy. *JAMA Surg* 152:540– 726
548 727
37. Baker TA, Aaron JM, Borge M, Pierce K, Shoup M, Aranha GV 728
(2008) Role of interventional radiology in the management of compli- 729
cations after pancreaticoduodenectomy. *Am J Surg* 195:386–390 730
discussion 390 731
38. Pedrazzoli S, Liessi G, Pasquali C, Ragazzi R, Berselli M, Sperti C 732
(2009) Postoperative pancreatic fistulas: preventing severe compli- 733
cations and reducing reoperation and mortality rate. *Ann Surg* 249: 734
97–104 735
39. Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Yamao J, Kim 736
S, Matsui Y, Takai S, Mergental H, Kamiyama Y (2008) A new 737
guideline to reduce postoperative morbidity after 738
pancreaticoduodenectomy. *Pancreas* 37:128–133 739
40. Liang TB, Bai XL, Zheng SS (2007) Pancreatic fistula after 740
pancreaticoduodenectomy: diagnosed according to International 741
Study Group Pancreatic Fistula (ISGPF) definition. *Pancreatology* 742
7:325–331 743
41. Bressan AK, Wahba M, Dixon E, Ball CG (2018) Completion 744
pancreatectomy in the acute management of pancreatic fistula after 745
pancreaticoduodenectomy: a systematic review and qualitative syn- 746
thesis of the literature. *HPB (Oxford)* 20:20–27 747
42. Zhou YM, Zhou X, Wan T, Xu D, Si XY (2018) An evidence- 748
based approach to the surgical interventions for severe pancreatic 749
fistula after pancreatoduodenectomy. *Surgeon* 16:119–124 750
43. Floortje van Oosten A, Smits FJ, van den Heuvel DAF, van 751
Santvoort HC, Molenaar IQ (2019) Diagnosis and management 752
of postpancreatectomy hemorrhage: a systematic review and meta- 753
analysis. *HPB (Oxford)* 21:953–961 754
44. Ma T, Bai X, Chen W, Lao M, Jin G, Zheng K, Fu D, Yang F, Qin 755
R, Li X, Lou W, Zhang L, Jiang K, Wu P, Shao C, Liu A, Yang Y, 756
Ma Y, Wu H, Liang T (2019) Surgical management and outcome of 757
grade-C pancreatic fistulas after pancreaticoduodenectomy: a retro- 758
spective multicenter cohort study. *Int J Surg* 68:27–34 759
45. Boverie JH, Remont A (1990) Percutaneous management of fistu- 760
las in the digestive tract. In: Dondelinger RF, Rossi P, Kurdziel JC 761
et al (eds) *Interventional radiology*. Georg Thieme Verlag, 762
Stuttgart, pp 746–752 763
46. D'Harcour JB, Boverie JH, Dondelinger RF (1996) Percutaneous 764
management of enterocutaneous fistulas. *AJR Am J Roentgenol* 765
167:33–38 766
47. Futagawa Y, Imazu H, Mori N, Kanazawa K, Chiba M, Furukawa 767
K, Sakamoto T, Shiba H, Yanaga K (2017) The effectiveness and 768
feasibility of endoscopic ultrasound-guided transgastric drainage of 769
postoperative fluid collections early after pancreatic surgery. *Surg* 770
Laparosc Endosc Percutan Tech 27:267–272 771
48. Al Efishat M, Attiyeh MA, Eaton AA, Gönen M, Covey AM, 772
D'Angelica MI, DeMatteo RP, Kingham TP, Balachandran V, 773
Jarnagin WR, Gerdes H, Allen PJ, Schattner MA (2019) 774
Endoscopic versus percutaneous drainage of post-operative 775
peripancreatic fluid collections following pancreatic resection. 776
HPB (Oxford) 21:434–443 777
49. De Pastena M, Paiella S, Marchegiani G, Malleo G, Ciprani D, 778
Gasparini C, Secchettin E, Salvia R, Bassi C (2017) Postoperative 779
infections represent a major determinant of outcome after 780
pancreaticoduodenectomy: results from a high-volume center. 781
Surgery 162:792–801 782
50. Yang F, Jin C, Li J, Di Y, Zhang J, Fu D (2018) Clinical signifi- 783
cance of drain fluid culture after pancreaticoduodenectomy. *J* 784
Hepatobiliary Pancreat Sci 25:508–517 785

- 786 51. Tomimaru Y, Tanaka K, Noguchi K, Noura SO, Imamura H, Iwazawa T, Dono K (2020) Significance of fistulography findings to the healing time of postoperative pancreatic fistula after pancreaticoduodenectomy. *Surg Today* 50:577–584
- 787
- 788 52. Takeda Y, Saiura A, Inoue Y, Mise Y, Ishizawa T, Takahashi Y, Ito H (2020) Early fistulography can predict whether biochemical leakage develops to clinically relevant postoperative pancreatic fistula. *World J Surg* 44:1252–1259
- 790
- 791 53. Urbach DR, Kennedy ED, Cohen MM (1999) Colon and rectal anastomoses do not require routine drainage: a systematic review and meta-analysis. *Ann Surg* 229:174–180
- 792
- 793 54. Petrowsky H, Demartines N, Rousson V, Clavien PA (2004) Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. *Ann Surg* 240:1074–1084 discussion 1084–1085
- 794
- 795 55. Wang Z, Chen J, Su K, Dong Z (2015) Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. *Cochrane Database Syst Rev* 5:CD008788
- 796
- 797 56. Witzigmann H, Diener MK, Kienkötter S, Rossion I, Bruckner T, Werner B, Pridöhl O, Radulova-Mauersberger O, Lauer H, Knebel P, Ulrich A, Strobel O, Hackert T, Büchler MW (2016) No need for routine drainage after pancreatic head resection: the dual-center, randomized, controlled PANDRA trial (ISRCTN04937707). *Ann Surg* 264:528–537
- 798
- 799 57. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr (2013) A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. *J Am Coll Surg* 216:1–14
- 800
- 801 58. Miller BC, Christein JD, Behrman SW, Drebin JA, Pratt WB, Callery MP, Vollmer CM Jr (2014) A multi-institutional external validation of the fistula risk score for pancreatoduodenectomy. *J Gastrointest Surg* 18:172–179 discussion 179–180
- 802
- 803 59. McMillan MT, Fisher WE, Van Buren G 2nd, McElhany A, Bloomston M, Hughes SJ, Winter J, Behrman SW, Zyromski NJ, Velanovich V, Brown K, Morgan KA, Vollmer C (2015) The value of drains as a fistula mitigation strategy for pancreatoduodenectomy: something for everyone? Results of a randomized prospective multi-institutional study. *J Gastrointest Surg* 19:21–30 discussion 30–31
- 804
- 805 60. Kawai M, Tani M, Terasawa H, Ina S, Hirono S, Nishioka R, Miyazawa M, Uchiyama K, Yamaue H (2006) Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients. *Ann Surg* 244:1–7
- 806
- 807 61. McMillan MT, Malleo G, Bassi C, Allegrini V, Casetti L, Drebin JA, Esposito A, Landoni L, Lee MK, Pulvirenti A, Roses RE, Salvia R, Vollmer CM Jr (2017) Multicenter, prospective trial of selective drain management for pancreatoduodenectomy using risk stratification. *Ann Surg* 265:1209–1218
- 808
- 809 62. Trudeau MT, Maggino L, Chen B, McMillan MT, Lee MK, Roses R, DeMatteo R, Drebin JA, Vollmer CM Jr (2020) Extended experience with a dynamic, data-driven selective drain management protocol in pancreaticoduodenectomy: progressive risk stratification for better practice. *J Am Coll Surg* 230:809–818
- 810
- 811 63. Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, Terpstra OT, Zijlstra JA, Klinkert P, Jeekel H (2004) Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. *Ann Surg* 240:738–745
- 812
- 813 64. Hüttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW, Diener MK (2016) Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. *Cochrane Database Syst Rev* 2:CD006053
- 814
- 815 65. Menahem B, Guittet L, Mulliri A, Alves A, Lubrano J (2015) Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. *Ann Surg* 261:882–887
- 816
- 817 66. Zhang X, Ma L, Gao X, Bao H, Liu P, Aziz A, Wang Z, Gong P (2015) Pancreaticogastrostomy versus pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. *Surg Today* 45:585–594
- 818
- 819 67. Jin Y, Feng YY, Qi XG, Hao G, Yu YQ, Li JT, Peng SY (2019) Pancreatogastrostomy vs pancreatojejunostomy after pancreaticoduodenectomy: an updated meta-analysis of RCTs and our experience. *World J Gastrointest Surg* 11:322–332
- 820
- 821 68. Schulick RD (2011) Use of pancreatic duct stents after pancreaticoduodenectomy. *J Hepatobiliary Pancreat Sci* 18:775–778
- 822
- 823 69. Nappo G, Perinel J, El Bechwaty M, Adham M (2016) The standardization of pancreatoduodenectomy: where are we? *Pancreas* 45:493–502
- 824
- 825 70. Dong Z, Xu J, Wang Z, Petrov MS (2016) Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy. *Cochrane Database Syst Rev* 5:CD008914
- 826
- 827 71. Marchegiani G, Perri G, Pulvirenti A, Sereni E, Azzini AM, Malleo G (2018) Non-inferiority of open passive drains compared with closed suction drains in pancreatic surgery outcomes: a prospective observational study. *Surgery* 164:443–449
- 828
- 829 72. Ejaz A, Tsung A, Dillhoff M, Pawlik TM, Cloyd JM (2020) Suction or gravity: impact of closed-system drain type on the postoperative outcomes of pancreatoduodenectomy. *Am Surg* 86:e69–e72
- 830
- 831 73. Gachabayov M, Gogna S, Latifi R, Dong XD (2019) Passive drainage to gravity and closed-suction drainage following pancreatoduodenectomy lead to similar grade B and C postoperative pancreatic fistula rates. A meta-analysis. *Int J Surg* 67:24–31
- 832
- 833 74. Deng Y, He S, Cheng Y, Cheng N, Gong J, Gong J, Zeng Z, Zhao L (2020) Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. *Cochrane Database Syst Rev* 3:CD009621
- 834
- 835 75. Liu X, Pausch T, Probst P, Cui J, Wei J, Hackert T, Miao Y (2020) Efficacy of pasireotide for prevention of postoperative pancreatic fistula in pancreatic surgery: a systematic review and meta-analysis. *J Gastrointest Surg* 24:1421–1429
- 836
- 837 76. Li T, D'Cruz RT, Lim SY, Shelat VG (2020) Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection - a systematic review & meta-analysis. *Pancreatology* 20:158–168
- 838
- 839
- 840
- 841
- 842
- 843
- 844
- 845
- 846
- 847
- 848
- 849
- 850
- 851
- 852
- 853
- 854
- 855
- 856
- 857
- 858
- 859
- 860
- 861
- 862
- 863
- 864
- 865
- 866
- 867
- 868
- 869
- 870
- 871
- 872
- 873
- 874
- 875
- 876
- 877
- 878
- 879
- 880
- 881
- 882
- 883
- 884
- 885
- 886
- 887
- 888
- 889
- 890
- 891
- 892
- 893
- 894
- 895
- 896
- 897
- 898
- 899
- 900
- 901
- 902
- 903
- 904
- 905
- 906
- 907
- 908
- 909
- 910
- 911
- 912

Commentary [A11]: After careful reflection, we deliberately opted for a pooled analysis in the previous version of the paper. Whether a pooled analysis of raw data or a meta-analysis of effect estimates should be carried out depends on the research question. In the presence of high heterogeneity among studies (like in the present case) and a high number of studies, a pooled analysis may be preferable. The current version of the paper reports also the results obtained from a meta-analysis. To account for the large heterogeneity among the studies, we used DerSimonian and Laird's (1986) method. A fixed effects moderator model was then used to compare the meta-analyzed incidence. The DL incidences are in line with the pooled incidence; however, the resources used in the pooled analysis (total number of patients) are two orders of magnitude larger than those used in the meta-analysis (number of studies). This explains the large difference between the corresponding two *P* values.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.